ClinicalTrials.gg
RecruitingNCT04385290MOSAICUpdated Sep 8, 2025

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

A Phase 1/2 interventional study of MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO and MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO in Acute Myeloid Leukemia, sponsored by Technische Universität Dresden. Recruiting at 21 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Technische Universität Dresden · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies testing midostaurin in Leukemia, Myeloid, Acute — 3 open to participants now, 5 under way, 1 of them phase 3. midostaurin · Leukemia, Myeloid, Acute.

Planned enrollment
6th of 28
214 · median 34
Started
2020
with 1 other
Phase 1/2
5 of 28
1 open now
Registered
26th of 28
by date
Lead sponsor
2 of 28
Technische Universität Dresden

Among the 28 studies testing midostaurin in Leukemia, Myeloid, Acute, this one is the 6th largest by planned enrollment, is one of 2 that started in 2020, is one of 5 in phase 1/2, and was the 26th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

3 of the 28 studies testing midostaurin in Leukemia, Myeloid, Acute are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About midostaurin

midostaurin: first FDA approval 2017 (RYDAPT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing midostaurin in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine Kinase 3 (FLT3) mutation.

Read the detailed description

Acute myeloid leukemia is a malignancy that is still fatal for the majority of patients. Besides age, the genetic configuration of AML blasts is one of the strongest prognostic factors. Patients with mutations in the core-binding factor (CBF) genes have the best prognosis, however a considerable proportion of 35-60% will eventually relapse. Mutation and overexpression of receptor tyrosinkinases (RTK) have been proposed as main reasons for relapse development or chemoresistance in CBF AMLs. RTKs like stem cell factor receptor (c-KIT) and FLT3 are of high clinical relevance as they mediate proliferation and differentiation of hematopoietic stem cells. There is evidence that c-Kit mutations and high levels of c-KIT in CBF-AML have adverse effects on survival endpoints indicating c-KIT as potential therapeutic target in this special AML population. Midostaurin can be considered a potent c-KIT inhibitor besides having multi-kinase inhibitory activity for several other kinases of documented or potential pathogenetic relevance for AML, most importantly mutated FLT3. The kinase inhibition ultimately leads to inhibition of proliferation, cell cycle arrest, and apoptosis. Previous studies with other c-KIT inhibitors such as dasatinib showed promising results with respect to survival end points in newly diagnosed CBF AML patients. Midostaurin is considered a more potent c-KIT inhibitor than dasatinib and may be able to potentiate the inhibitory effect on leukemic cell growth.

Another important therapeutical target in CBF AML is the sialic acid-binding immunoglobulin-like lectin (CD33) which is expressed on the majority of AML blasts. Gemtuzumab Ozogamicin (GO) is a therapeutic CD33 antibody linked to a strong cytostatic drug (calicheamicin) which causes apoptosis of cancer cells upon internalization. For the combination of GO and standard intensive chemotherapy, metaanalyses of randomized trials have shown that i) a low-dose fractionated administration results in the best tolerability, and ii) among AML subgroups, patients with CBF AML have the greatest benefit from GO in addition to standard therapy. Subgroup analyses within the ALFA-0701 (A Randomized Study of Gemtuzumab Ozogamicin With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia Aged of 50-70 Years Old) trial population showing beneficial effects of GO on overall survival, relapse-free survival and event-free survival in patients positive for FLT3 mutation as compared to those negative for FLT3 mutation. Subgroup analyses of the GO registration trial ALFA-0701 showed a significant clinical benefit of the patients displaying a mutation in the FLT3 gene compared to those without this mutation. In Addition, CBF AML patients with FLT3 mutations expressed particularly high levels of CD33 antigen and that CD33 antigen levels were positively correlated to the improved survival after GO treatment. Furthermore, recently published data of two paediatric populations with internal tandem mutation in the FLT3 gene showed reduced relapse rates in GO recipients compared to the control group only receiving standard chemotherapy. These results suggest that GO is a particularly beneficiary agent in FLT3 mutated patients who would currently receive midostaurin in addition to intensive chemotherapy as a standard of care. Hence, from a clinical point of view there is an unambiguous rationale supporting the combination of midostaurin and GO for treatment of AML in the two cytogenetic subgroups: CBF AML and FLT3 mutated AML.

GO has become the new treatment standard for patients with CBF AML. The hypothesized positive effect of midostaurin is likely but randomized proof is laking.

Midostaurin has become the new treatment standard for AML patients with mutations in the FLT3 gene. The positive effect of GO is shown in a post-hoc subgroup analysis of the ALFA-0701 trial, but prospective randomized proof is lacking.

Therefore, the proposed trial intends i) to explore and establish the safe combination of GO plus midostaurin (MODULE) and ii) to evaluate the effect of midostaurin versus no midostaurin added to standard AML chemotherapy plus GO in CBF AML (MAGNOLIA) and iii) to evaluate the effect of GO versus no GO added to standard AML chemotherapy plus midostaurin in FLT3 mutated AML (MAGMA).

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML
  • FLT3 mutation
  • CBF
  • midostaurin
  • gemtuzumab ozogamicin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Newly diagnosed AML according to the criteria of the World Health Organisation plus the following molecular or cytogenetic specifications:

    • Phase I Trial - MODULE:

      • t(8;21)/RUNX1-RUNX1T1 or
      • inv(16) or t(16;16)/CBFB-MYH11 or
      • FLT3-ITD or
      • FLT3-tyrosine kinase domain (FLT3-TKD)
    • Phase II Trial - MAGNOLIA

      • t(8;21)/RUNX1-RUNX1T1 or
      • inv(16) or t(16;16)/CBFB-MYH11
    • Phase II Trial - MAGMA

      • FLT3-ITD or
      • FLT3-TKD
      • Absence of mutations in CBF genes (i.e. t(8;21)/RUNX1-RUNX1T1 or inv(16) or t(16;16)/CBFB-MYH11)
  • Male and female patients aged

    • 18 - ≤ 75 years in Phase I Trial - MODULE
    • 18 - ≤ 70 years in Phase II Trials - MAGMA and MAGNOLIA
  • (ECOG) Score of 0-2
  • > 14 days
  • Adequate hepatic and renal function

    • / aspartate transaminase ≤ 2.5 x
    • \< 2 x upper limits of normal
    • Creatinine \< 1.5 x upper limits of normal or > 40 ml/min
  • White blood cell count \< 30 × 10\^9/L. Note: Hydroxyurea and/or a dose of 100-200 mg/m\^2 cytarabine per day for up to 3 days (for emergency use for clinical stabilization) is permitted to meet this criterion.

Exclusion criteria

Exclusion Criteria (all study parts):

  • Previous antineoplastic treatment for AML other than hydroxyurea and/or cytarabine for emergency use (100-200 mg/m\^2 per day on maximal 3 days)
  • Previous treatment with anthracyclines
  • central nervous system involvement
  • Isolated extramedullary AML
  • Uncontrolled infection
  • AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g., azacytidine or decitabine)
  • Any agent within 30 days or 5 half-lives, whichever is greater, prior to day 1. An investigational agent is defined as an agent with no approved medical use in adults or in pediatric patients
  • Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib)
  • Strong /5 enzyme inducing drugs unless they can be discontinued or replaced prior to enrollment
  • Any other known disease or concurrent severe and/or uncontrolled medical condition (e.g., cardiovascular disease including congestive heart failure or active uncontrolled infection) that could compromise participation in the study
  • Impairment of gastrointestinal (GI) function or GI disease that might alter significantly the absorption of midostaurin
  • Confirmed diagnosis of infection,
  • Active viral hepatitis unless serology demonstrates clearance of infection. Occult or prior virus (HBV) infection, defined as negative hepatitis B surface antigen and positive total hepatitis core antibodies, may be included if HBV DNA is undetectable, provided that patients are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior cured hepatitis B are eligible. Patients for virus (HCV) antibody are eligible provided PCR is negative for HCV RNA.
  • Cardiovascular abnormalities, including any of the following:

    • History of myocardial infarction, angina pectoris, Coronary Artery Bypass Grafting within 6 months prior to starting study treatment
    • Clinically uncontrolled cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II and third degree atrioventricular block)
    • Uncontrolled congestive heart failure
    • of \< 50%
    • Poorly controlled arterial hypertension
  • Pregnant or nursing (lactating) women
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they fulfill at least one of the following criteria:

    • (12 months of natural amenorrhea or 6 months of amenorrhea with serum follicule stimulating hormone > 40 U/ml)
    • Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy
    • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days before the first dose of study drug
    • Continuous and correct application of a method with a Pearl Index of \< 1% (e.g. implants, depots, oral contraceptives, intrauterine device) from initial study drug administration until at least 7 months after the last dose of gemtuzumab ozogamicin and at least 4 months after the last dose of midostaurin, whichever period is longer. A hormonal contraception method must always be combined with a barrier method (e.g. condom)
    • Sexual abstinence
    • Vasectomy of the sexual partner
  • Sexually active males unless they use a condom during intercourse while taking the drug during treatment, and for at least 4 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via semen
  • Unwillingness or inability to comply with the protocol
  • Known to midostaurin, GO, cytarabine or daunorubicin or to any of the of midostaurin, GO, cytarabine or daunorubicin.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (estimated)

Study arms

  • Experimental
    MODULE trial: dose escalation

    Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m\^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m\^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m\^2 i.v. on days 1 to 3).

    Drug: MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO

  • Experimental
    MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin

    Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML

    Drug: MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO

  • Active comparator
    MAGNOLIA-trial: conventional chemotherapy+GO

    Phase II (Trial part MAGNOLIA): treatment standard of CBF AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v. plus GO (3 mg/m\^2 i.v. max 4.5 mg) on days 1, 4, 7). No additional Midostaurin is given.

    Drug: MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO

  • Experimental
    MAGMA-trial: conventional chemotherapy+midostaurin and GO

    Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML

    Drug: MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin

  • Active comparator
    MAGMA-trial: conventional chemotherapy+midostaurin

    Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v plus midostaurin). No additional GO is given.

    Drug: MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin

Interventions

  • DrugMODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO

    Drug page: MidostaurinStudies of MidostaurinMidostaurin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level GO (IMP) induction: 3 mg/m\^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level Daunorubicin (DNR, non-IMP) induction: 60 mg/m\^2/day i.v., days 1 to 3 Cytarabine (AraC, non-IMP) induction: 200 mg/m\^2/day cont. infusion, days 1 to 7

    Also known as: Rydapt, Mylotarg

  • DrugMAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO

    Drug page: MidostaurinStudies of MidostaurinMidostaurin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Midostaurin (IMP): RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles; GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only Daunorubicin (DNR, non-IMP): 60 mg/m\^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders Cytarabine (AraC, non-IMP): 200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Also known as: Rydapt, Mylotarg

  • DrugMAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO

    Drug page: GemtuzumabStudies of GemtuzumabGemtuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg on days 1, 4, 7; 1 induction cycle only Daunorubicin (DNR, non-IMP): 60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders Cytarabine (AraC, non-IMP): 200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Also known as: Mylotarg

  • DrugMAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin

    Drug page: GemtuzumabStudies of GemtuzumabGemtuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Midostaurin (IMP): RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles; GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only Daunorubicin (DNR, non-IMP): 60 mg/m\^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders Cytarabine (AraC, non-IMP): 200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Also known as: Mylotarg, Rydapt

  • DrugMAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin

    Drug page: MidostaurinStudies of MidostaurinMidostaurin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Midostaurin (IMP): RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles Daunorubicin (DNR, non-IMP): 60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders Cytarabine (AraC, non-IMP): 200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Also known as: Rydapt

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of midostaurin and GO combination

    as measured by the number of dose limiting toxicities related to midostaurin or GO exposure.

    Time frame: treatment day 8 until day 42 at the latest

  2. Event Free Survival (EFS)

    Time interval from date of randomization until either primary treatment failure or relapse or death, whichever occurs first.

    Time frame: up to 3 years from enrolment

Secondary outcomes

  1. CR/CRi rate

    CR/CRi rate is defined as the proportion of patients, who achieved a morphologic complete remission or a complete remission with incomplete hematologic recovery (CR or CRi) during study participation.

    Time frame: after induction treatment, approx. 2 months

  2. Duration of remission

    Duration of remission is defined as time interval from date of CR/CRi until morphologic relapse.

    Time frame: up to 3 years from enrolment

  3. Cumulative incidence of relapse

    Cumulative incidence of relapse is defined as the time interval from date of first CR/CRi until relapse.

    Time frame: up to 3 years from enrolment

  4. Relapse-free survival

    Relapse-free survival is defined as the time interval from date of first CR/CRi until either morphologic relapse or death in remission.

    Time frame: up to 3 years from enrolment

  5. Overall survival

    Overall survival is defined as time interval from date of randomization until death from any cause.

    Time frame: up to 3 years from enrolment

  6. Early mortality rate

    Early mortality is defined as death from any reason within 30 days and 60 days from start of induction.

    Time frame: 30 and 60 days after commencement of therapy

07

Study locations

19 of 21 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Apr 2027, 79 months after the start.

Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's planned 79 months is close to that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2020
First posted
May 12, 2020
StartActual
Sep 4, 2020
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04385290
Responsible party
Sponsor
First posted
May 12, 2020
Start date
Sep 4, 2020
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 8, 2025

Study contacts

Christoph Röllig, Prof. Dr.
Contact
MOSAIC@ukdd.de
+49 351 458 ext. 3775
Manja Reimann, Dr.
Contact
MOSAIC@ukdd.de
+49 351 458 ext. 3091
Christoph Röllig, Prof. Dr.
principal investigator · Technische Universität Dresden, Medical Faculty Carl Gustav Carus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midostaurin · Gemtuzumab

Start the discussion